Marker Therapeutics treats first OTS MAR-T patient

Marker Therapeutics, Inc. reported that it has treated the first patient in its Off-the-Shelf (OTS) program evaluating the company’s Multi-Antigen Recognizing (MAR)-T cell therapy.

Rhea-AI Filing Summary

Marker Therapeutics, Inc. reported that it has treated the first patient in its Off-the-Shelf (OTS) program evaluating the company’s Multi-Antigen Recognizing (MAR)-T cell therapy. This marks the initial use of its OTS MAR-T product in a clinical setting, an important step in moving the therapy from development into human testing. The update was shared through a press release dated October 6, 2025, which is included as an exhibit to the report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Marker Therapeutics (MRKR) announce in this 8-K filing?

Marker Therapeutics announced that the first patient has been treated in its Off-the-Shelf (OTS) program evaluating the company’s Multi-Antigen Recognizing (MAR)-T cell therapy, as described in a press release dated October 6, 2025.

What is the focus of Marker Therapeutics’ OTS program mentioned in the filing?

The OTS program focuses on evaluating Marker Therapeutics’ Off-the-Shelf Multi-Antigen Recognizing (MAR)-T cell therapy in patients, and this filing notes that the first patient has now been treated under this program.

How was the first patient treatment disclosed by Marker Therapeutics (MRKR)?

The company disclosed the first patient treatment in its OTS MAR-T program through a press release issued on October 6, 2025, which is attached to the report as Exhibit 99.1.

Which exhibit in the 8-K filing contains more details on Marker Therapeutics’ first OTS MAR-T treatment?

Exhibit 99.1 to the report is a press release dated October 6, 2025, which contains additional details about the first patient treated in the OTS program evaluating Marker’s MAR-T cell therapy.

Who signed the Marker Therapeutics (MRKR) 8-K related to the OTS MAR-T program?

The report was signed on behalf of Marker Therapeutics, Inc. by Juan Vera, who is the company’s President and Chief Executive Officer.

On which exchange is Marker Therapeutics’ common stock listed?

Marker Therapeutics’ common stock, par value $0.001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol MRKR.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/06/2025 - 07:30 AM Learn about SEC filing dates

false 0001094038 0001094038 2025-10-06 2025-10-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 6, 2025

Date of Report (Date of earliest event reported)

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-37939	45-4497941
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2450 Holcombe Blvd, TMC Partners Office 1.311 Houston, Texas		77021
(Address of principal executive offices)		(Zip Code)

(713) 400-6400

Registrant’s telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		MRKR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Information

On October 6, 2025, Marker Therapeutics, Inc. (“Marker” or the “Company”) issued a press release announcing that the first patient had been treated in the Company’s Off-the-Shelf (“OTS”) Program evaluating Marker’s Multi-Antigen Recognizing (MAR)-T cell therapy.

A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release, dated October 6, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Marker Therapeutics, Inc.
Dated: October 6, 2025	By:	/s/ Juan Vera
		Juan Vera
		President and Chief Executive Officer